Pharmacokinetics of actinoymcin D in patients with malignant melanoma.
about
A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies.Intestinal and liver toxicity of antineoplastic drugs.Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.Persistent DNA damage-induced premature senescence alters the functional features of human bone marrow mesenchymal stem cells.In vitro sensitivity of human ovarian tumours to chemotherapeutic agents.Enhancement of human chorionic gonadotrophin production by antimetabolites.Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.Association of nbl gene expression and glucocorticoid-induced apoptosis in mouse thymus in vivo.Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d.Upregulation of heat shock protein 27 confers resistance to actinomycin D-induced apoptosis in cancer cells.The current role of cancer chemotherapy.Establishment and characterization of a cell line (DEOC-1) originating from a human malignant melanoma of the skin.Population pharmacokinetic investigation of actinomycin-D in children and young adults.Rapid screening and characterization of metabolites from a marine-derived actinomycete by high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight mass spectrometry.In vitro effect of actinomycin D on human neutrophil function.Actinomycin D suppresses radiation transformation in vitro.In vitro responses of human prostate tumour cell lines to a range of antitumour agents.Identification of Steroidogenic Components Derived From Gardenia jasminoides Ellis Potentially Useful for Treating Postmenopausal Syndrome.
P2860
Q33459619-2B722449-A523-4691-A580-6FE6A627FBEEQ33605823-E863B813-9E73-4FB8-AF1D-3E7817F732EBQ33832954-20B0A6AB-AD8C-4699-A31F-96D25410C6C8Q35390924-1F6F3D17-0DD9-4445-83DF-64130C0C5F08Q36045431-48CC7575-A9AA-4C68-B8DB-E04CDD6930ADQ36046693-794BCE5A-F7C0-4AD2-8566-A0E1A77DEAE1Q36533306-DA027AD9-1442-454F-8A50-63A131D5A541Q36689682-6836AA41-CC10-4DC0-B9E8-85898E74E3C4Q36806598-3175674C-116A-40E8-9811-7A823EFA599CQ37424554-8B6BA54C-4653-41EA-9F00-E055AFB7E138Q39126758-73662B4A-B948-4CD9-8C46-50D1CEDE19C5Q39776420-787BD6A0-F7D5-48B3-8112-E7445CCE072AQ40124292-D18AA4AC-9EA1-4480-8425-CBD01B3A3DD8Q40142021-424C9EB5-C991-40AD-9A6C-A3B6F912B600Q42820560-2C3ABFD8-0A51-482C-8143-8F378FD1F801Q50467062-23E0C3C5-D85A-4A94-BFBE-BD80A1A077ACQ53575281-AA88344F-2FC3-4C28-A82E-CD21C04876EAQ54491062-02C73CDD-CE73-462C-B7A9-00AB689B3CC1Q55024426-BEAE2B04-4139-4997-B107-85FB8DAD3D08
P2860
Pharmacokinetics of actinoymcin D in patients with malignant melanoma.
description
1975 nî lūn-bûn
@nan
1975年の論文
@ja
1975年学术文章
@wuu
1975年学术文章
@zh
1975年学术文章
@zh-cn
1975年学术文章
@zh-hans
1975年学术文章
@zh-my
1975年学术文章
@zh-sg
1975年學術文章
@yue
1975年學術文章
@zh-hant
name
Pharmacokinetics of actinoymcin D in patients with malignant melanoma.
@en
Pharmacokinetics of actinoymcin D in patients with malignant melanoma.
@nl
type
label
Pharmacokinetics of actinoymcin D in patients with malignant melanoma.
@en
Pharmacokinetics of actinoymcin D in patients with malignant melanoma.
@nl
prefLabel
Pharmacokinetics of actinoymcin D in patients with malignant melanoma.
@en
Pharmacokinetics of actinoymcin D in patients with malignant melanoma.
@nl
P2093
P356
P1476
Pharmacokinetics of actinoymcin D in patients with malignant melanoma.
@en
P2093
Dengupta SK
Frei E 3rd
Sodergren JE
Tattersall MH
P304
P356
10.1002/CPT1975176701
P407
P577
1975-06-01T00:00:00Z